目的 :探讨肿瘤标志物Cyfra2 1 1在喉癌、喉咽癌早期诊断、病程进展、治疗监测中的作用。方法 :应用酶联免疫夹心抗体对 30例正常人、8例咽喉部良性肿瘤、32例喉癌、喉咽癌患者手术前后进行血清Cyfra2 1 1测定。结果 :喉癌、喉咽癌患者Cyfra2 1 1明显高于正常人及良性肿瘤患者 (P <0 0 1)。喉癌、喉咽癌术后半月Cyfra2 1 1明显下降 ,与正常人比较差异无显著性 ,Cyfra2 1 1与肿瘤TNM分期呈正相关。 结论 :Cyfra2 1 1作为一种新的肿瘤标志物 ,对喉癌和喉咽癌的病程进展、治疗监测和预后判断有重要临床价值。 Objective: To investigate the role of tumor marker Cyfra2 1 1 in the early diagnosis of laryngeal cancer and hypopharyngeal carcinoma, the course of disease and the monitoring of the treatment. Methods: Serum Cyfra2 1 1 levels were measured in 30 normal subjects, 8 benign throat benign tumors, 32 laryngeal cancer and hypopharyngeal cancer patients before and after operation by enzyme-linked immunosorbent sandwich antibody. Results: Cyfra2 1 1 was significantly higher in patients with laryngeal and hypopharyngeal carcinoma than in normal and benign tumors (P <0.01). The laryngeal cancer and hypopharyngeal cancer after a half months Cyfra2 1 1 decreased significantly, compared with the normal no significant difference, Cyfra2 1 1 and tumor TNM stage was positively correlated. Conclusion: Cyfra2 1 1 as a new tumor marker has important clinical value for the progression of disease, treatment monitoring and prognosis of laryngeal and hypopharyngeal carcinoma.